Experimental antibody takes on tough bile duct cancers
NCT ID NCT05297903
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental drug called XmAb20717 in 27 adults with advanced biliary tract cancers (bile duct or gallbladder cancer) that worsened after standard chemotherapy. The drug is a bispecific antibody designed to activate the immune system against cancer by blocking two checkpoints (PD-1 and CTLA-4). Researchers are measuring how many patients' tumors shrink or disappear, and how long they live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XmAb20717 (a bispecific antibody that targets two immune checkpoints, PD-1 and CTLA-4)
- What this could lead to
- If successful, this could provide a new treatment option for patients with advanced biliary tract cancers who have run out of standard chemotherapy options.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply to all patients. The drug may cause immune-related side effects and may not shrink tumors in everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers